274 related articles for article (PubMed ID: 30478962)
1. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
2. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract][Full Text] [Related]
4. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
Tian T; Ye J; Zhou S
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
6. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
7. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
8. [Two Cases of Unresectable/Advanced Breast Cancer with Pathological Complete Response after Combination Chemotherapy with Pertuzumab. Trastuzumab, and Docetaxel].
Tomida K; Kawai Y; Mori T; Kitamura M; Kato H; Sakai S; Shimizu T; Umeda T; Tatsumi M; Shimada K; Tani M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2435-2437. PubMed ID: 30692489
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
[TBL] [Abstract][Full Text] [Related]
12. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
14. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
15. Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
Stroes CI; Schokker S; Creemers A; Molenaar RJ; Hulshof MCCM; van der Woude SO; Bennink RJ; Mathôt RAA; Krishnadath KK; Punt CJA; Verhoeven RHA; van Oijen MGH; Creemers GJ; Nieuwenhuijzen GAP; van der Sangen MJC; Beerepoot LV; Heisterkamp J; Los M; Slingerland M; Cats A; Hospers GAP; Bijlsma MF; van Berge Henegouwen MI; Meijer SL; van Laarhoven HWM
J Clin Oncol; 2020 Feb; 38(5):462-471. PubMed ID: 31809243
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
Kaidar-Person O; Billan S; Kuten A
Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
[TBL] [Abstract][Full Text] [Related]
17. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.
van Boxtel W; Boon E; Weijs WLJ; van den Hoogen FJA; Flucke UE; van Herpen CML
Oral Oncol; 2017 Sep; 72():198-200. PubMed ID: 28673692
[No Abstract] [Full Text] [Related]
18. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.
De Placido S; Giuliano M; Schettini F; Von Arx C; Buono G; Riccardi F; Cianniello D; Caputo R; Puglisi F; Bonotto M; Fabi A; Bilancia D; Ciccarese M; Lorusso V; Michelotti A; Bruzzese D; Veneziani BM; Locci M; De Laurentiis M; Arpino G
Breast; 2018 Apr; 38():86-91. PubMed ID: 29287189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
